Phenotype
|
Fish
|
Conditions
|
Figures
|
brain glycosphingolipid increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 7
from Ikeda et al., 2021
|
brain lamp1a expression increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 8
from Ikeda et al., 2021
|
brain oxt expression decreased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 6
from Ikeda et al., 2021
|
brain pmch expression decreased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 6
from Ikeda et al., 2021
|
whole organism Ab2-lamp1 labeling increased amount, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 3
from Sahashi et al., 2022
|
aggressive behavior decreased occurrence, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 2
from Ikeda et al., 2021
|
brain tfeb expression increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 8
from Ikeda et al., 2021
|
brain nr3c2 expression decreased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 6
from Ikeda et al., 2021
|
pronephros lysosome increased amount, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 3
from Sahashi et al., 2022
|
brain Ab2-lamp1 labeling increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 8
from Ikeda et al., 2021
|
intestine lysosome increased amount, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 3
from Sahashi et al., 2022
|
social behavior disrupted, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 1
from Ikeda et al., 2021
|
whole organism ab1-map1lc3b labeling increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Fig. 5
from Sahashi et al., 2022
|
macrophage lysosome decreased functionality, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 3
from Sahashi et al., 2022
|
whole organism gpx1a expression increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Fig. 5
from Sahashi et al., 2022
|
whole organism sod1 expression increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Fig. 5
from Sahashi et al., 2022
|
whole organism ab2-sqstm1 labeling decreased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Fig. 5
from Sahashi et al., 2022
|
whole organism nos2b expression increased amount, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 2
from Sahashi et al., 2022
|
brain galns expression increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 8
from Ikeda et al., 2021
|
brain ctsa expression increased amount, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 8
from Ikeda et al., 2021
|
whole organism mpeg1.1 expression increased amount, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 2
from Sahashi et al., 2022
|
whole organism increased distance whole organism, abnormal
|
neu1zf3377/zf3377
|
standard conditions
|
Figure 1
from Ikeda et al., 2021
|
whole organism decreased life span, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 1
from Sahashi et al., 2022
|
whole organism aif1l expression increased amount, abnormal
|
neu1zf3377/zf3377
|
bacterial treatment by exposure to environment: Edwardsiella piscicida
|
Fig. 2
from Sahashi et al., 2022
|
liver alpha-sialidase activity decreased process quality, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 3
from Okada et al., 2020
|
muscle lamp1a expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
peripheral olfactory organ lysosome increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 4
from Okada et al., 2020
|
muscle mmp9 expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
muscle tfeb expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
whole organism alpha-sialidase activity decreased process quality, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 3
from Okada et al., 2020
|
brain lysosome increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 4
from Okada et al., 2020
|
pericardial cavity edematous, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 5
from Okada et al., 2020
|
bone tissue mmp9 expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 7
from Okada et al., 2020
|
brain sirt1 expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 5
from Okada et al., 2020
|
whole organism myog expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
bone tissue runx2b expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 7
from Okada et al., 2020
|
whole organism myog expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
whole organism decreased life span, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
text only
from Okada et al., 2020
|
muscle connective tissue cell distended, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 5
from Okada et al., 2020
|
vertebral column curved, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 5
from Okada et al., 2020
|
whole organism dead, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
text only
from Okada et al., 2020
|
whole organism myod1 expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
muscle ctsa expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
bone tissue runx2a expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 7
from Okada et al., 2020
|
whole organism myod1 expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 6
from Okada et al., 2020
|
whole organism neu3.2 expression increased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 3
from Okada et al., 2020
|
whole organism exo-alpha-sialidase activity process quality, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 4
from Okada et al., 2020
|
whole organism locomotion decreased process quality, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 5
from Okada et al., 2020
|
muscle cell atrophied, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 5
from Okada et al., 2020
|
whole organism neu3.4 expression decreased amount, abnormal
|
neu1zf3377/zf3377 (RW)
|
standard conditions
|
Fig. 3
from Okada et al., 2020
|